ACLX [NASD]
Arcellx, Inc.
Index- P/E- EPS (ttm)-3.10 Insider Own9.20% Shs Outstand35.74M Perf Week2.20%
Market Cap812.04M Forward P/E- EPS next Y-4.55 Insider Trans8.67% Shs Float26.61M Perf Month48.14%
Income-86.10M PEG- EPS next Q-1.29 Inst Own61.40% Short Float2.96% Perf Quarter32.68%
Sales- P/S- EPS this Y-102.40% Inst Trans- Short Ratio3.40 Perf Half Y-
Book/sh10.67 P/B1.79 EPS next Y11.00% ROA- Target Price28.67 Perf Year-
Cash/sh4.96 P/C3.85 EPS next 5Y- ROE- 52W Range6.03 - 26.91 Perf YTD13.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.10% Beta-
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low216.16% ATR2.33
Employees78 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)61.13 Volatility8.97% 16.90%
OptionableNo Debt/Eq0.00 EPS Q/Q-496.70% Profit Margin- Rel Volume1.13 Prev Close18.60
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume231.78K Price19.08
Recom1.20 SMA207.11% SMA5046.77% SMA20032.33% Volume257,365 Change2.58%
Mar-01-22Initiated SVB Leerink Outperform $47
Mar-01-22Initiated BofA Securities Buy $24
Jun-23-22 10:50AM  
Jun-21-22 04:05PM  
04:01PM  
Jun-15-22 10:47PM  
Jun-10-22 05:00PM  
Jun-06-22 04:09PM  
Jun-03-22 04:00PM  
May-27-22 09:57AM  
May-23-22 04:05PM  
May-16-22 04:01PM  
May-12-22 04:01PM  
May-10-22 04:01PM  
May-09-22 04:01PM  
10:00AM  
May-05-22 04:01PM  
Apr-27-22 10:00AM  
Apr-08-22 01:00PM  
Mar-24-22 04:01PM  
Mar-10-22 04:26PM  
Mar-08-22 05:25PM  
Feb-08-22 04:01PM  
01:54PM  
Feb-04-22 05:03PM  
02:49PM  
01:57AM  
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
New Enterprise Associates 15, 10% OwnerJun 21Buy16.00312,5005,000,0006,745,262Jun 23 05:10 PM